The LAMEA indapamide market is estimated to grow significantly during the forecast period. The factors contributing to the growth of the indapamide market include rising cases of diabetes and hypertension among the population. According to the International Diabetes Federation (IDF), Brazil and Mexico are the two countries with a higher number of diabetes cases registered in the region. In Mexico, an estimated 12 million cases were registered in 2017. Additionally, the diabetes cases are expected to rise by 35% to an estimated 16 million cases by 2045 in Mexico. Moreover, according to the World Health Organization (WHO), diabetes is the second-most common cause of mortality in Mexico. Hence, indapamide drugs have great potential to offer for diabetes in the market of the RoW region. Some of the major factors that are contributing to the increasing cases of diabetes include rapid urbanization and changing lifestyles across the region.
(Get 25% Discount on Buying this Report)
To learn more about this report request a free sample copy @ https://www.omrglobal.com/request-sample/lamea-indapamide-market
The LAMEA indapamide market is segmented on the basis of product and application. Based on the product, the market is bifurcated into 1.25 mg indapamide and 2.5 mg indapamide. Among these, the market for 1.25 mg medicine held a significant share owing to the extensive application of the drug in treating high blood pressure or hypertension. Based on the application, the market is segmented into high blood pressure, heart failure, and others. The high blood pressure segment is projected to have a significant share in the market. Growing incidence of hypertension is contributing to market growth as indapamide drugs are significantly used to treat hypertension while reducing the risk of developing serious heart conditions.
Some of the global companies operating in the LAMEA indapamide market include ANI Pharmaceuticals, Inc., Apotex Inc., Sanofi S.A., Teva Pharmaceuticals Industries Ltd., Mylan N.V., and others. The market players are considerably contributing to market growth by adopting various strategies to stay competitive in the market.
Latin America and Middle & Africa (LAMEA) Indapamide Market- Segmentation
By Product
- 25 MG
- 5 MG
By Application
- High Blood Pressure
- Heart Failure
- Others
A full report of Latin America and Middle & Africa (LAMEA) Indapamide Market is available at: https://www.omrglobal.com/industry-reports/lamea-indapamide-market
Latin America and Middle & Africa (LAMEA) Indapamide Market– Segment by Region
- Latin America
- Middle East
- Africa
